Epratuzumab
- Generic Name
- Epratuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-57-5
- Unique Ingredient Identifier
- 3062P60MH9
- Background
Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.
- Indication
Investigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
- Associated Conditions
- -
- Associated Therapies
- -
Inotuzumab Ozogamicin in Pediatric Patients With Relapsed or Refractory B-Cell ALL
The review highlights inotuzumab ozogamicin's role in treating pediatric ALL, particularly R/R ALL, and evolving therapeutic options. It emphasizes the drug's FDA approval for pediatric patients, its efficacy in clinical trials, and ongoing research to improve ALL treatment strategies.
Related Clinical Trials:
New Agents for Targeted Treatment of Lymphoma
Advances in understanding lymphoma's molecular biology have identified potential therapeutic targets, leading to new agents like monoclonal antibodies and small-molecule inhibitors. Despite progress, drug development remains slow, with challenges in identifying 'driver' molecular defects and predictive biomarkers. The review highlights the need for focused research to accelerate the approval of promising drugs for lymphoma treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath